Work package 5: Phase II clinical trial in Burkina Faso
Led by Groupe de Recherche Action en Santé, Burkina Faso
The main objectives of this work package are:
To continue clinical development of ShigaPlexIM in a descending age study of safety and immunogenicity in a phase II trial.
To determine the safety and immunogenicity of two formulations of InvaplexAR-Detox in participants 10-17 years, 24-59 months and 6-11 months of age, given as three doses four weeks apart at D1, D22 and D43.